Researchers at the University of Calgary in Canada are conducting further trials after early studies revealed that vitamin B3, or niacin, holds promise in restoring immune function in the fight against glioblastoma, a brain cancer that grows aggressively and is hard to treat. The findings, which have yet to be confirmed in larger clinical studies, suggest that niacin may boost the effectiveness of standard treatments such as radiotherapy and chemotherapy.
Glioblastoma is one of the most aggressive forms of brain cancer, with a median survival rate of approximately 15 months. Current standard of care includes surgery, radiation, and chemotherapy, but the tumor often recurs. The University of Calgary’s research focuses on the role of niacin in enhancing the immune system’s ability to target cancer cells. Niacin is known to play a role in cellular metabolism and DNA repair, but its potential in oncology is a relatively new area of study.
“If results are good, it could open the door to using combination treatments that include niacin and other future therapies,” the researchers noted. The study is particularly relevant for companies developing glioblastoma treatments, such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP), which is indicated for glioblastoma and other brain cancers.
The importance of this research lies in its potential to provide a low-cost, readily available supplement that could improve outcomes for patients with limited treatment options. Niacin is widely available and generally considered safe at recommended doses, making it an attractive candidate for combination therapy.
However, experts caution that the early results are preliminary and require validation through rigorous clinical trials. The University of Calgary team is currently enrolling patients in a larger study to determine the optimal dosage and confirm the efficacy of niacin in combination with standard therapies.
If proven effective, niacin could become a standard adjunct therapy for glioblastoma, offering hope to thousands of patients diagnosed each year. The research also underscores the potential of repurposing common vitamins and nutrients for cancer treatment, a field that has gained increasing attention in recent years.
For more information on the latest developments in biotechnology and life sciences, follow BioMedWire, a specialized communications platform focused on the Biotech, Biomedical, and Life Sciences sectors.
